The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection [clinicaltrials:NCT00001036]
The Safety and Effectiveness of a Type of Interleukin-2 Plus Zidovudine Plus Thymosin in HIV-Positive Patients With and Without Symptoms of Infection [clinicaltrials:NCT00001036]
Bio2RDF identifier
NCT00001036
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00001036
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
To determine the safety ...... receiving AZT and PEG IL-2.
brief title [clinicaltrials_vocabulary:brief-title]
The Safety and Effectiveness o ...... Without Symptoms of Infection
condition [clinicaltrials_vocabulary:condition]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
AIDS is characterized b ......
an additional 8 weeks.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-02T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Acquired Immunodeficiency Syndrome
Adjuvants, Immunologic
Drug Therapy, Combination
Interleukin-2
Polyethylene Glycols
T-Lymphocytes
Zidovudine
thymosin alpha(1)
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2008-07-29T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
link [clinicaltrials_vocabulary:link]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00001036
official title [clinicaltrials_vocabulary:official-title]
Safety and Efficacy of Polyeth ...... ic and Symptomatic Individuals
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
reference [clinicaltrials_vocabulary:reference]
source [clinicaltrials_vocabulary:source]
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
1996-10-01T00:00:00Z
identifier
clinicaltrials:NCT00001036
title
The Safety and Effectiveness o ...... Without Symptoms of Infection
@en
type
label
The Safety and Effectiveness o ...... n [clinicaltrials:NCT00001036]
@en